• Wed, February 2, 2022
Dennis Ding Upgraded (ABUS) to Strong Buy and Increased Target to $5 on, Feb 2nd, 2022
Dennis Ding of Jefferies, Upgraded "Arbutus Biopharma Corporation" (ABUS) to Strong Buy and Increased Target from $4 to $5 on, Feb 2nd, 2022.
Dennis has made no other calls on ABUS in the last 4 months.
There is 1 other peer that has a rating on ABUS. Out of the 1 peers that are also analyzing ABUS, 0 agree with Dennis's Rating of Hold.
This is the rating of the analyst that currently disagrees with Dennis
- Jason Butler of "JMP Securities" Maintained at Buy with Increased Target to $9 on, Monday, November 8th, 2021
Like: 👍
